---
title: "Nucala (mepolizumab), all indications: Pharmacology questions"
description: "Pharmacology questions on Nucala (mepolizumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pharmacokinetics and Components. Questions: How is Nucala metabolized? What are the inactive ingredients in Nucala? Does Nucala contain latex? 3 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/nucala/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Nucala (mepolizumab), all indications: Pharmacology questions

Manufacturer: GlaxoSmithKline  
Prescribing information: [Nucala](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF)  
Indication pages: [Severe eosinophilic asthma](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma)

## Pharmacokinetics

<a id="nucala-metabolism"></a>

### How is Nucala metabolized?

> “Metabolism: Mepolizumab is a humanized IgG1 monoclonal antibody that is degraded by the 
> proteolytic enzymes widely distributed in the body and not restricted to hepatic tissue.”

Source: [NUCALA: Prescribing information, page 18, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=18)

## Components

<a id="nucala-inactive-ingredients"></a>

### What are the inactive ingredients in Nucala?

> “NUCALA for injection is a sterile, preservative-free, white to off-white, lyophilized powder in a 
> single-dose vial for subcutaneous injection after reconstitution. Upon reconstitution with 1.2 mL 
> of Sterile Water for Injection, USP, the resulting concentration is 100 mg/mL and delivers 1 mL 
> [see Dosage and Administration (2.2)]. Each vial delivers 100 mg of mepolizumab, polysorbate 
> 80 (0.67 mg), sodium phosphate dibasic heptahydrate (7.14 mg), and sucrose (160 mg), with a 
> pH of 7.0.”

Source: [NUCALA: Prescribing information, page 15, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=15)

> “Each 1 mL delivers 100 mg mepolizumab, citric acid”

Source: [NUCALA: Prescribing information, page 15, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=15)

> “monohydrate (0.95 mg), EDTA disodium dihydrate (0.019 mg), polysorbate 80 (0.20 mg), 
> sodium phosphate dibasic heptahydrate (4.16 mg), and sucrose (120 mg), with a pH of 6.3.”

Source: [NUCALA: Prescribing information, page 16, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=16)

> “Each 0.4 mL delivers 40 mg mepolizumab, citric acid 
> monohydrate (0.38 mg), EDTA disodium dihydrate (0.0074 mg), polysorbate 80 (0.08 mg), 
> sodium phosphate dibasic heptahydrate (1.66 mg), and sucrose (48 mg), with a pH of 6.3.”

Source: [NUCALA: Prescribing information, page 16, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=16)

Note: The first passage concerns the vial; the second and third are one sentence on the 100 mg/mL autoinjector and syringe, divided by a page break; the fourth concerns the 40 mg/0.4 mL syringe.

<a id="nucala-latex"></a>

### Does Nucala contain latex?

> “The vial stopper is not made with natural rubber latex.”

Source: [NUCALA: Prescribing information, page 15, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=15)

> “The prefilled autoinjector and prefilled syringe are not made with natural rubber latex.”

Source: [NUCALA: Prescribing information, page 16, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=16)

## Related pages
- [Medical information: Nucala (mepolizumab): All indications](https://www.evicenter.com/medical-information/nucala)
- [Indication](https://www.evicenter.com/medical-information/nucala/indication)
- [Safety](https://www.evicenter.com/medical-information/nucala/safety)
- [Specific populations](https://www.evicenter.com/medical-information/nucala/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/nucala/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/nucala/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/nucala/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/nucala/access-and-coverage)
